Navigation Links
Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
Date:11/8/2012

LANCASTER, Pa. and ROCKVILLE, Md., Nov. 8, 2012 /PRNewswire/ -- Immunomic Therapeutics, Inc., ("ITI," Lancaster, PA) a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax™ vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan. JRC-LAMP-vax vaccine is a plasmid-based DNA vaccine that will be studied for its safety and immunological activity in the treatment of patients with rhino-conjunctivitis symptoms caused by allergic reaction to Japanese red cedar pollen. Enrollees in the study each received the first of a four (4) dosing vaccine regimen and were followed for 3 hours; no adverse events were observed in these patients.

ITI intends to complete enrollment in the study in November, the dosing of all patients early in 2013, and to follow up with a Phase II trial beginning in 2013. ITI's CEO, Dr. William Hearl, commented, "The successful initiation of this clinical study marks a significant milestone in the history of Immunomic Therapeutics. We are both pleased and excited that we are now a clinical - stage company. We are looking forward to completing the study and advancing the development of this important vaccine and other LAMP-vax™ vaccines."

Dr. Bruce F. Mackler, Vice President of Regulatory and Clinical Affairs, Immunomic Therapeutics, Inc., indicated that "ITI is committed to the rapid expansion of its clinical program based on the outcome of this first Japanese red cedar vaccine. We plan to move rapidly into the clinical testing of the multivalent vaccine in naturally sensitive Japanese ex-patriates as well as U.S. subjects with sensitivity to mountain cedar. This stu
'/>"/>

SOURCE Immunomic Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
2. Echo Therapeutics Announces Third Quarter 2012 Financial Results
3. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
4. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
5. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Novelos Therapeutics Closes $2 Million Private Placement
7. US Allows Two Key Patents for Silence Therapeutics
8. United Therapeutics Corporation Reports Third Quarter 2012 Financial Results
9. Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine Months Ended September 30, 2012 Compared to Same Periods in 2011
10. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
11. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... JOLLA, Calif. , Nov. 26, 2014   ... a biopharmaceutical company leading the discovery and development of ... G. Xanthopoulos , Ph.D., President and CEO of Regulus, ... Annual Piper Jaffray Healthcare Conference at the New ... 2:00 p.m. EST.  The presentation will be webcast at ...
(Date:11/26/2014)... ® , Inc. (NASDAQ: BIOS ) announced today that ... present at the Bank of America Merrill Lynch 2014 Leveraged Finance ... , , Wednesday, December 3, 2014 , , , , ... , Location: , , , Boca Raton Resort and Club, Florida ... BioScrip, Inc. is a leading national provider of infusion ...
(Date:11/26/2014)... 26, 2014 The medical magnetic resonance ... of 4%, with world market revenues for 2013 ... and other types of medical imaging have led ... numerous medical conditions in children and adults, each ... report, Medical Imaging Markets , analyzes the ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... ... of Body Mass Index -, PHILADELPHIA, Oct. 16 ... been,established, but healthcare professionals have had little guidance as to,whether ... with GERD. Two studies about obesity and its,relationship to GERD ...
... to File Supplemental New Drug Application with FDA in First ... ... FRANCISCO, Calif., Oct. 16 Anesiva,Inc. (Nasdaq: ANSV ) today ... randomized, double-blind study,with 699 adult patients met its primary endpoint, demonstrating ...
Cached Medicine Technology:Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 2Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 3Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 4Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms 5Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 2Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 3Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 4Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults 5
(Date:11/27/2014)... 28, 2014 One of the ... The market for implant dentistry comprises dental implants ... global market for dental care is bifurcated into ... dental equipment segment is composed of large equipment. ... at: http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The worldwide dental ...
(Date:11/27/2014)... Today, Digital-Signage-China.com adds 2 new items to its collection ... media player promotion for Dec. 2014. , The CEO ... in April, and this promotion will help to expand our ... models on our website, she/he can contact us with special ... models come in the latest designs, and they actually are ...
(Date:11/27/2014)... Turks and Caicos Islands; BWI (PRWEB) November 28, 2014 ... for the Tuscany Resort in the Turks & Caicos. ... resorts by TripAdvisor in Providenciales, is announcing a few ... three bedroom villa rentals. And they are offering ... resort. , Additionally, The Tuscany, is having a ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... Blood-borne pathogens raise the risk of spreading ... in place to counter this. However, it doesn’t seem ... with menstrual blood are taken as seriously. , ... way to handle tampons and menstrual pads while also ... , He then created a prototype of the Sani-M, ...
Breaking Medicine News(10 mins):Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2
... PHILADELPHIA A research team led by Nancy Speck, ... Perelman School of Medicine at the University of Pennsylvania, ... of hematopoietic (blood) stem cells (HSCs) in the developing ... from engineered precursors., Because HSCs, found in the bone ...
... FOR DEC. 9, 2011] The investigation of a 2009 ... (STEC), an important cause of bacterial gastrointestinal illness, led ... Published in Clinical Infectious Diseases and ... offers recommendations for prevention, including a stronger message for ...
... ANTONIO -- Precisely quantifying the amount of three different ... linked to breast cancer , did not predict ... Cancer with Herceptin, say Mayo Clinic researchers. HER2-positive ... human epidermal growth factor receptor 2 that promotes cancer ...
... quarter century of work in Malawi, a Michigan State ... MRI scans on children newly diagnosed with cerebral malaria ... Michael Potchen, an associate professor in the Department ... from the Dana Foundation, a private philanthropic organization supporting ...
... may help personalize pain medication management for sickle cell ... Dr. Cheedy Jaja, a nurse research scientist and ... National Institutes of Health grant to determine if variations ... opioids could help physicians manage sickle cell pain. ...
... blood test with other factors including the size of the ... up to one-quarter of men avoid biopsies and the risks ... team says. Writing in a study published online by ... G. Sanda, MD, Director of the Prostate Center at Beth ...
Cached Medicine News:Health News:Penn study unlocks origins of blood stem cells 2Health News:Ready-to-bake cookie dough not ready-to-eat, study of E. coli outbreak finds 2Health News:Proteins do not predict outcome of herceptin treatment in HER2-positive breast cancer 2Health News:Uncovering how cerebral malaria damages the brain 2Health News:Study probes genetic link to sickle cell pain management 2Health News:Study probes genetic link to sickle cell pain management 3Health News:Study probes genetic link to sickle cell pain management 4Health News:PSA testing, combined with other relevant patient data can reduce unnecessary prostate biopsies 2Health News:PSA testing, combined with other relevant patient data can reduce unnecessary prostate biopsies 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: